Magenta stops MGTA-117 Cohort 4 dosing after two DLTs; to continue at Cohort 3

Dianthus Therapeutics, Inc. /DE/

Three participants dosed in Cohort 4 (0.13 mg/kg); two had dose-limiting toxicities (respiratory SAEs).
First DLT was Grade 4 respiratory SAE; second DLT triggered pre-specified stopping rules.
No DLTs observed in fifteen participants across first three cohorts.
Three of four Cohort 3 participants with paired samples showed cancer blast depletion in blood and bone marrow.
Magenta reported first DLT to FDA; plans to enroll more patients at Cohort 3 (0.08 mg/kg).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.